BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 35183225)

  • 1. Improvement of peripheral neuropathy in a patient with antineutrophil cytoplasmic antibody-negative eosinophilic granulomatosis with polyangiitis by additional mepolizumab.
    Kai Y; Yoshikawa M; Matsuda M; Suzuki K; Ohara H; Iguchi N; Kasamatsu T; Uno K; Fujioka N; Fujita Y; Muro S
    Allergy Asthma Clin Immunol; 2022 Feb; 18(1):14. PubMed ID: 35183225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful early introduction of mepolizumab for peripheral neuropathy with a peripheral circulatory disorder in a patient with myeloperoxidase anti-neutrophil cytoplasmic antibody-negative eosinophilic granulomatosis with polyangiitis.
    Nishihara M; Hamaguchi M; Ikumi N; Nishiwaki A; Sugiyama K; Nagasawa Y; Tsuzuki H; Yoshizawa S; Tanikawa Y; Asatani S; Kobayashi H; Takei M; Kitamura N
    Mod Rheumatol Case Rep; 2021 Jul; 5(2):354-359. PubMed ID: 33970058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-neutrophil Cytoplasmic Antibody-negative Eosinophilic Granulomatosis with Polyangiitis Complicated with Peripheral Neuropathy that Underwent Remission Induction with Mepolizumab Monotherapy.
    Nishihara M; Suzuki M; Asatani S; Nagasawa Y; Tsukamoto M; Akiya K; Kobayashi H; Kitamura N; Nakamura H
    Intern Med; 2023 Oct; 62(19):2895-2900. PubMed ID: 36725044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful Treatment of Eosinophilic Granulomatosis With Polyangiitis: A Case of Refractory Peripheral Neuropathy and Comorbid Chronic Progressive Pulmonary Aspergillosis Treated With Mepolizumab.
    Sekiya R; Soma T; Nakagome K; Nagata M
    Cureus; 2024 Jan; 16(1):e52192. PubMed ID: 38222984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mepolizumab administration for eosinophilic granulomatosis with polyangiitis in an elderly patient with an abrupt onset of limb ischaemia and peripheral neuropathy: A case-based literature review.
    Terashima S; Yamaguchi M; Ishihara T; Hagita J; Katsuno T; Ito M; Sugiyama H; Iwagaitsu S; Nobata H; Kinashi H; Ishimoto T; Banno S; Ito Y
    Mod Rheumatol Case Rep; 2023 Jan; 7(1):142-147. PubMed ID: 36107735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Pediatric Case of Relapsing Eosinophilic Granulomatosis with Polyangiitis Successfully Treated with Mepolizumab.
    Nara M; Saito M; Abe F; Komatsuda A; Wakui H; Takahashi N
    Intern Med; 2019 Dec; 58(24):3583-3587. PubMed ID: 31391393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement of Chronic Rhinosinusitis and Reduction of the Myeloperoxidase-Antineutrophil Cytoplasmic Antibody Titer in a Patient with Eosinophilic Granulomatosis with Polyangiitis by Additional Mepolizumab.
    Tamechika SY; Isogai S; Maeda S; Naniwa T; Niimi A
    Case Rep Rheumatol; 2021; 2021():5561762. PubMed ID: 33859858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mepolizumab as the first targeted treatment for eosinophilic granulomatosis with polyangiitis: a review of current evidence and potential place in therapy.
    Faverio P; Bonaiti G; Bini F; Vaghi A; Pesci A
    Ther Clin Risk Manag; 2018; 14():2385-2396. PubMed ID: 30573961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A patient with eosinophilic granulomatosis with polyangiitis successfully weaned from corticosteroids through remission induction therapy with mepolizumab.
    Ueno M; Miyagawa I; Kawabe A; Kusaka K; Nakayamada S; Tanaka Y
    Mod Rheumatol Case Rep; 2022 Jun; 6(2):243-247. PubMed ID: 35366318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis.
    Ennis D; Lee JK; Pagnoux C
    Expert Opin Biol Ther; 2019 Jul; 19(7):617-630. PubMed ID: 31146595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Case of Effective Mepolizumab Induction Therapy for Severe Eosinophilic Granulomatosis with Polyangiitis Diagnosed by Eosinophilic Cholecystitis and Interstitial Nephritis.
    Hattori K; Teramachi Y; Kobayashi Y; Ito T; Morinaga T; Tamai H; Yamamoto Y
    Case Rep Rheumatol; 2021; 2021():6678893. PubMed ID: 34239754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis.
    McBrien CN; Menzies-Gow A
    Drugs Today (Barc); 2018 Feb; 54(2):93-101. PubMed ID: 29637936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Efficacy of Mepolizumab in Patients with Eosinophilic Granulomatosis with Polyangiitis.
    Pradhan RR; Nepal G; Mandal S
    Pulm Med; 2019; 2019():4376380. PubMed ID: 30941214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis.
    Steinfeld J; Bradford ES; Brown J; Mallett S; Yancey SW; Akuthota P; Cid MC; Gleich GJ; Jayne D; Khoury P; Langford CA; Merkel PA; Moosig F; Specks U; Weller PF; Wechsler ME
    J Allergy Clin Immunol; 2019 Jun; 143(6):2170-2177. PubMed ID: 30578883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term Safety and Efficacy of Benralizumab for Eosinophilic Granulomatosis with Polyangiitis Complicated with Severe Neuropathy.
    Koga Y; Yoshimi S; Harada T; Suzuki S; Ohtsuka T; Dobashi K; Hisada T
    Intern Med; 2023 May; 62(10):1553-1556. PubMed ID: 36171130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A case of subarachnoid haemorrhage associated with MPO-ANCA-positive eosinophilic granulomatosis with polyangiitis, successfully treated with glucocorticoid, cyclophosphamide, and mepolizumab.
    Satake Y; Sakai S; Takao T; Saeki T
    Mod Rheumatol Case Rep; 2023 Dec; ():. PubMed ID: 38109745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perspectives on the Efficacy of Benralizumab for Treatment of Eosinophilic Granulomatosis With Polyangiitis.
    Koga Y; Aoki-Saito H; Kamide Y; Sato M; Tsurumaki H; Yatomi M; Ishizuka T; Hisada T
    Front Pharmacol; 2022; 13():865318. PubMed ID: 35359852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mepolizumab as a glucocorticoid-sparing agent in eosinophilic granulomatosis with polyangiitis (EGPA): is a lower dose sufficient?
    Vergles M; Matković Z; Lalić K; Trkanjec JT; Tudorić N
    J Asthma; 2021 Dec; 58(12):1675-1679. PubMed ID: 32962455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab and mepolizumab combination therapy for glucocorticoid-resistant myocarditis related to eosinophilic granulomatosis with polyangiitis.
    Higashitani K; Yoshimi R; Sato Y; Watanabe T; Ihata A
    Mod Rheumatol Case Rep; 2022 Jan; 6(1):87-92. PubMed ID: 34473835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-Dose Mepolizumab Effectiveness in Patients Suffering From Eosinophilic Granulomatosis With Polyangiitis.
    Vultaggio A; Nencini F; Bormioli S; Vivarelli E; Dies L; Rossi O; Parronchi P; Maggi E; Matucci A
    Allergy Asthma Immunol Res; 2020 Sep; 12(5):885-893. PubMed ID: 32638567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.